Clinical trials: Eosinophilia
Eosinophilic Esophagitis
Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)
This is a prospective single center clinical trial of allergen-specific immune signature-guided dietary elimination therapy to assess the clinical effectiveness of this technique.
- Trial name
- IDiET (NCT02722148)
- Testing
- Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophilic Esophagitis
Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
The purpose of this study is to assess the clinical efficacy of proton pump inhibitors in comparison to aerosolized swallowed steroids for the treatment of eosinophilic esophagitis (EE).
- Trial name
- NCT00895817
- Testing
- Swallowed fluticasone, Esomeprazole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Walter Reed Army Medical Center
Eosinophilic Esophagitis
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)
The purpose of this study is to test the safety and effectiveness of Losartan potassium in subjects with eosinophilic esophagitis (EoE) including those with a connective tissue disorder (CTD) and those without a CTD.
- Trial name
- NCT03029091
- Testing
- Losartan Potassium
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00255346
- Testing
- Dasatinib (BMS-354825)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control.
- Trial name
- NCT02281318
- Testing
- Mepolizumab, SOC
- Where
- 144 sites in United States, Argentina and 17 more
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
The primary aim of this study was to determine the proportion of patients with esophageal eosinophilic infiltration that have objective (measurable) evidence of gastroesophageal reflux disease (GERD).
- Conditions
- Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
- Trial name
- NCT00728481
- Testing
- Esomeprazole, Budesonide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Mayo Clinic
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
COPD, Eosinophilia
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
- Trial name
- COPD-HELP (NCT04075331)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- University of Leicester
Chronic Rhinosinusitis (Diagnosis), Nasal Polyps
Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Benralizumab will be used in a placebo controlled randomized study to treat severe chronic rhinosinusitis with nasal polyps
- Conditions
- Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Eosinophilia
- Trial name
- NCT03450083
- Testing
- Benralizumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Eosinophilia, Hypereosinophilic Syndrome
Steroid Treatment for Hypereosinophilic Syndrome
Background: Hypereosinophilic syndrome (HES) is a disorder in which the body has too many eosinophils (a type of white blood cell). Too many eosinophils in HES can cause damage to the heart, nerves, or skin.
- Conditions
- Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder, Hematologic Diseases
- Trial name
- NCT01524536
- Testing
- prednisone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Esophagitis
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
Eosinophilic esophagitis (EE) is an increasingly recognized condition characterized by dysphagia, food impaction or other obstructive esophageal symptoms in children and young adults.
- Trial name
- NCT00123630
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Hypereosinophilic Syndrome
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a…
- Trial name
- NCT02836496
- Testing
- Mepolizumab 300 mg, Active OCS capsules (5 mg prednisolone or prednisone)
- Where
- 43 sites in United States, Argentina and 11 more
- Volunteers
- 108 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Esophagitis
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434).
- Trial name
- NCT00635089
- Testing
- reslizumab
- Where
- 36 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Ception Therapeutics
Eosinophilic Asthma
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma.
- Trial name
- NCT03469934
- Testing
- Etokimab
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- AnaptysBio, Inc.
Eosinophilic Esophagitis
Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment…
- Trial name
- NCT02019758
- Testing
- Oral Viscous Budesonide, Fluticasone MDI
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophilic Asthma
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
- Trial name
- NCT05002621
- Testing
- Observational
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Eosinophilic Esophagitis
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms.
- Trial name
- FLUTE (NCT03191864)
- Testing
- APT-1011
- Where
- 75 sites in United States, Belgium and 4 more
- Volunteers
- 106 people
- Sponsor
- Adare Pharmaceuticals, Inc.